secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARTIVION, INC. (AORT)
CIK:        0000784199
Form:       8-K
Filed at:   2024-12-09T23:59:59+00:00
Accession:  0000784199-24-000254
Event type: regulatory
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants Artivion HDE for AMDS Hybrid Prosthesis in acute DeBakey Type I dissections with malperfusion
--------------------------------------------------------------------------------

- HDE covers ~40% of US acute DeBakey Type I dissections; PMA expected late 2025 for full $150M annual market.
- PERSEVERE trial: 72% reduction in all-cause mortality, 54% reduction in major adverse events vs. standard hemiarch at 30 days.
- AMDS is world's first aortic arch remodeling device; previously granted Breakthrough and HUD designations.
- Company to begin IRB approvals, VAC submissions, and surgeon training to prepare for commercial launch.
- Enterprise shareholders to receive 0.60 Independent shares + $2.00 cash per share; total consideration ~$562M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/784199/000078419924000254/0000784199-24-000254-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/784199/000078419924000254/aort-20241209.htm
  HTML page:      https://secwatch.observer/filing/0000784199-24-000254

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer